QSV Equity Investors LLC Reduces Position in Catalyst Pharmaceuticals, Inc. $CPRX

QSV Equity Investors LLC decreased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 36.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 53,438 shares of the biopharmaceutical company’s stock after selling 30,426 shares during the period. QSV Equity Investors LLC’s holdings in Catalyst Pharmaceuticals were worth $1,160,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Huntington National Bank grew its position in shares of Catalyst Pharmaceuticals by 105.0% during the second quarter. Huntington National Bank now owns 1,433 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 734 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Catalyst Pharmaceuticals by 57.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 2,002 shares during the period. US Bancorp DE grew its position in Catalyst Pharmaceuticals by 17.8% during the 1st quarter. US Bancorp DE now owns 7,328 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 1,105 shares during the last quarter. Headlands Technologies LLC acquired a new position in Catalyst Pharmaceuticals in the first quarter valued at $188,000. Finally, Quarry LP raised its holdings in shares of Catalyst Pharmaceuticals by 60.0% in the first quarter. Quarry LP now owns 8,000 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 3,000 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 30,000 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $20.30, for a total transaction of $609,000.00. Following the transaction, the insider directly owned 271,039 shares in the company, valued at approximately $5,502,091.70. This represents a 9.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Carmen Jeffrey Del sold 10,983 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $23.33, for a total transaction of $256,233.39. Following the sale, the insider owned 3,962 shares of the company’s stock, valued at approximately $92,433.46. The trade was a 73.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 10.40% of the company’s stock.

Wall Street Analysts Forecast Growth

CPRX has been the topic of a number of research reports. Zacks Research lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Catalyst Pharmaceuticals in a research report on Wednesday, October 8th. Oppenheimer reissued an “outperform” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Wall Street Zen raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Finally, Citigroup boosted their price objective on shares of Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Buy” and an average target price of $32.67.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $23.10 on Thursday. The business has a 50 day simple moving average of $21.55 and a 200-day simple moving average of $21.69. The stock has a market capitalization of $2.84 billion, a P/E ratio of 13.43, a P/E/G ratio of 0.81 and a beta of 0.69. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.05 and a 12 month high of $26.58.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Monday, September 25th. The biopharmaceutical company reported $0.28 earnings per share for the quarter. The firm had revenue of $53.11 million for the quarter. Catalyst Pharmaceuticals had a return on equity of 39.24% and a net margin of 37.63%. Research analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.9 EPS for the current year.

Catalyst Pharmaceuticals declared that its board has authorized a stock repurchase plan on Wednesday, October 1st that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the biopharmaceutical company to purchase up to 8.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.